Can-Fite BioPharma Files 6-K, Incorporates Press Release
Ticker: CANF · Form: 6-K · Filed: Dec 16, 2025 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Dec 16, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, registration-statement
TL;DR
Can-Fite BioPharma filed a 6-K on 12/16/25, linking to prior S-8/F-3 filings.
AI Summary
On December 16, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release. This filing is relevant to several of their existing Registration Statements on Form S-8 and Form F-3, indicating ongoing or updated disclosures related to securities offerings or other corporate actions.
Why It Matters
This filing updates or supplements existing SEC filings, which could impact investors' understanding of the company's current status and any related securities transactions.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that incorporates a press release and references existing registration statements, not indicating new material events or financial distress.
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Filer of the 6-K report
- December 16, 2025 (date) — Date of the filing and press release incorporation
- Form S-8 (document) — Registration statement referenced in the filing
- Form F-3 (document) — Registration statement referenced in the filing
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that provides information which the issuer makes or is required to make public pursuant to the laws of the issuer's home country, or which it furnishes or makes public to its security holders.
Which specific Registration Statements are being updated by this 6-K filing?
This 6-K filing incorporates information into Can-Fite BioPharma's Registration Statements on Form S-8 (File Nos. 333-227753, 333-271384, and 333-278525) and Form F-3 (File Nos. 333-236064, 333-274316, 333-262055, 333-276000, and 333-281872).
What is the exact filing date of this Form 6-K?
The Form 6-K was filed on December 16, 2025.
What is the primary business of Can-Fite BioPharma Ltd. according to the filing?
Can-Fite BioPharma Ltd. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Where is Can-Fite BioPharma Ltd. headquartered?
Can-Fite BioPharma Ltd. is headquartered at 26 Ben Gurion Street, Ramat Gan, Israel.
Filing Stats: 263 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2025-12-16 09:21:05
Filing Documents
- ea0269855-6k_canfite.htm (6-K) — 11KB
- ea026985501ex99-1_canfite.htm (EX-99.1) — 13KB
- 0001213900-25-121959.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: December 16, 2025 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 3